Contemporary rends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States

Allard C. B., Gelpi-Hammerschmidt F., Harshman L. C., Choueiri T. K., Faiena I., Modi P., ...Daha Fazla

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, cilt.33, sa.11, 2015 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 11
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/j.urolonc.2015.06.014
  • Dergi Adı: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: High-dose interleukin-2, Immunotherapy, Renal cell carcinoma, Kidney cancer, Therapy trends, Toxicity, INTERFERON-ALPHA, DOUBLE-BLIND, CANCER, STATISTICS, SURVIVAL, ANTIBODY, MELANOMA, SAFETY
  • Marmara Üniversitesi Adresli: Evet

Özet

Background: Targeted therapies (TTs) have revolutionized metastatic renal cell carcinoma (mRCC) treatment in the past decade, largely replacing immunotherapy including high-dose interleukin-2 (HD IL-2) therapy. We evaluated trends in HD IL-2 use for mRCC in the IT era.